Paper Details

  1. Home
  2. Paper Details

A novel dopamine receptor D2 antagonist (ONC206) potentiates the effects of olaparib in endometrial cancer.

Author: AllenJoshua E, Bae-JumpVictoria, FanYali, HaoTianran, HawkinsGabrielle M, ParaghamianSarah E, PrabhuVarun Vijay, QiuJianqing, SunWenchuan, SuoHongyan, ZhangXin, ZhaoZiyi, ZhouChunxiao

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

PARP inhibitors are effective for cancers with homologous recombination deficiencies. ONC206, an imipridone, has anti-tumor effects in endometrial cancer by inducing apoptosis and modulating PI3K/AKT signaling. This study found that combining olaparib (a PARP inhibitor) with ONC206 showed synergistic anti-proliferative effects, increased apoptosis, and reduced tumor growth in endometrial cancer cell lines and a mouse model.
Paper Details　
Original Abstract of the Article :
Poly ADP-ribose polymerase (PARP) inhibitors are effective therapies for cancer patients with homologous recombination (HR) deficient tumors. The imipridone ONC206 is an orally bioavailable dopamine receptor D2 antagonist and mitochondrial protease ClpP agonist that has anti-tumorigenic effects in e...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10115124/

データ提供：米国国立医学図書館（NLM）

A Novel Combination Therapy for Endometrial Cancer

The fight against cancer is a continuous battle, requiring innovative strategies to outmaneuver this formidable foe. This research explores the potential of combining [ONC206], a novel [dopamine receptor D2 antagonist], with the PARP inhibitor [olaparib] for the treatment of [endometrial cancer]. The researchers, like seasoned warriors, explore the synergistic effects of these drugs, aiming to develop a more potent and effective treatment regimen. This research is like a strategic alliance in a desert war, combining forces to overcome a formidable enemy.

Synergistic Effects in Endometrial Cancer

The findings suggest that the combination of ONC206 and olaparib exhibits [synergistic anti-proliferative effects] in endometrial cancer cells, leading to increased cellular stress and apoptosis. This discovery is like finding a new weapon that can effectively target the enemy's defenses. The combination therapy also demonstrates a significant reduction in tumor weight in a [genetically engineered mouse model] of endometrial cancer, highlighting its potential for clinical application.

Exploring New Avenues for Endometrial Cancer Treatment

This research opens up new avenues for treating endometrial cancer, offering a promising combination therapy that could lead to improved patient outcomes. The findings are like finding a hidden oasis in the desert of cancer research, offering hope for a more effective and targeted treatment approach.

Dr.Camel's Conclusion

This research is a testament to the power of innovation in cancer research. The discovery of synergistic effects between ONC206 and olaparib in endometrial cancer is like discovering a new weapon in the fight against this deadly disease. The research is a promising step towards developing more effective and targeted therapies, offering hope for a brighter future for patients with endometrial cancer.

Date :
  1. Date Completed 2023-04-19
  2. Date Revised 2023-06-11
Further Info :

Pubmed ID

37069726

DOI: Digital Object Identifier

PMC10115124

Related Literature

Article Analysis
・Effects of olaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.